Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label ziftomenib monotherapy in Japanese patients with relapsed or refractory NPM1-mutated AML
jRCT2031250550Phase 2Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ziftomenib in acute myeloid leukemia (AML), sponsored by Kyowa Kirin. Primary endpoint: CR+CRh rate. Started Apr 2026; status: recruiting.
02
Drugs
ziftomenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2031250550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250550.